Dipòsit Digital de Documents de la UAB
Publicación
Artículo científico (JournalArticle)
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies. CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Proyecto:
Ministerio de Economía y Competitividad PI13/01714
,
Ministerio de Economía y Competitividad CP14/00228
,
Ministerio de Economía y Competitividad MV15/00041
,
Instituto de Salud Carlos III PI20/00892
,
Ministerio de Economía y Competitividad FJCI-2015-25412
,
Ministerio de Economía y Competitividad AC15/00062
,
Ministerio de Economía y Competitividad CB16/12/00449
,
Instituto de Salud Carlos III PI19/01181
,
Ministerio de Economía y Competitividad PI16/00904
,
Instituto de Salud Carlos III PI19/01846